Project Grant F32AI188687
- This $450,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Arkansas for Medical Sciences (UAMS) aims to enhance the understanding of macrophage subsets in tuberculosis (TB) infection and lesion biology. The project will leverage the C3HeB/FeJ mouse model, which forms the caseous necrotic lesions observed in human TB, to investigate how different lung macrophage subsets influence...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $813,450 to Case Western Reserve University to conduct research evaluating human T cells specific for Mycobacterium tuberculosis (MTB) antigens that are processed and presented by infected macrophages. The objective is to gain insight into which MTB antigens are presented and the composition and kinetics of the T cell repertoire targeting these...
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (PDCs) in Mycobacterium tuberculosis (MTB) infection. The research aims to quantify PDC trafficking and activation in the lungs during MTB infection, and determine how PDC-driven type I interferon responses impact MTB control. The project will leverage a mouse model that...
- This $492,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to conduct biochemical and structural characterization of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and the model organism Mycobacterium smegmatis. The research will use bacterial genetics and endogenous protein purifications to understand how these critical protein systems coordinate and interact to...
- This $227,096 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Berkeley to investigate nutrient acquisition strategies utilized by the tuberculosis pathogen Mycobacterium tuberculosis (MTB) during infection of human macrophages. The researchers have developed a novel genetic screening technique called Random Barcode Transposon Site Sequencing (RB-TnSeq) to...
- This $194,940 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with a start date of August 12, 2025 and an ultimate completion date of July 31, 2030. The primary goal of this research project is to discover the global human genetic regulators, including genes and genetic variants, that control macrophage antimicrobial responses to Mycobacterium tuberculosis (MTB) infection....
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- This Project Grant award of $192,500.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to determine how prior diverse microbial experiences influence the course of tuberculosis (TB) infection. The project will leverage a novel "dirty" mouse model that exposes specific pathogen-free (SPF) mice to a diverse microbiome to shape the immune response, and compare outcomes to traditional SPF mice....
- This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research at Yale University to develop an in vitro culture system that can be used to screen for small molecule inhibitors of drug-tolerant Mycobacterium tuberculosis (MTB) bacteria. The key objectives are to: 1) identify the subcellular environment and carbon source associated with drug-tolerant MTB, and 2) design in vitro...
ELUCIDATING SPATIO-TEMPORAL INNATE IMMUNE CELL MODULATION OF MYCOBACTERIUM TUBERCULOSIS STRESS RESPONSE AND REPLICATION HETEROGENEITY - PROJECT SUMMARY/ABSTRACT HETEROGENEITY, INCLUDING IN MYCOBACTERIUM TUBERCULOSIS (MTB) REPLICATION STATUS AND LOCAL ENVIRONMENT, IS A HALLMARK OF MTB INFECTION AND STRONGLY IMPACTS INFECTION OUTCOME AND DISEASE TREATMENT. SPATIAL ORGANIZATION OF MTB LESIONS IN THE LUNG AFFECT ENVIRONMENTAL SIGNALS THAT THE BACTERIA RECEIVE, WITH CONSEQUENT EFFECTS ON MTB STRESS RESPONSES AND GROWTH. FOR EXAMPLE, MTB WITHIN THE NECROTIC LESION CORE ARE EXTRACELLULAR, WHILE MTB IN THE LESION CUFF RESIDE WITHIN IMMUNE CELLS, RESULTING IN EXPOSURE TO DIFFERENT OXYGEN LEVELS, PH AND NITRIC OXIDE (NO) STRESS, AMONG OTHER SIGNALS. MTB ALSO EXHIBITS SHIFTS IN METABOLISM OVER THE COURSE OF INFECTION, WITH LIPID METABOLISM VITAL AS INFECTION PROGRESSES AND LIPID-RICH FOAMY MACROPHAGES FORM. IMPORTANTLY, ENVIRONMENTAL NON-UNIFORMITY EXISTS EVEN WITHIN EACH LESION SUBLOCATION, LIKELY DRIVEN BY PROXIMITY TO/RESIDENCE IN DIFFERENT IMMUNE CELL TYPES AND THEIR SPECIALIZED ANTIMICROBIAL PROGRAMMING. CONSISTENT WITH THIS HYPOTHESIS, WE OBSERVE A GREATER DEPENDENCE ON INTERSTITIAL MACROPHAGES (IMS) IN CONTROLLING MTB GROWTH IN NECROTIC LESIONS VERSUS ALVEOLAR MACROPHAGES (AMS). DIFFERENT ANTIMICROBIAL EFFECTORS IN AMS AND IMS MAY CONTRIBUTE TO THIS DIFFERENCE IN CONTROLLING MTB GROWTH. NOTABLY, WE OBSERVE AN INCREASE IN EXTRACELLULAR LIPID LEVELS IN THE PERIPHERY OF THE NECROTIC LESION CORE UPON MACROPHAGE DEPLETION, CORRESPONDING WITH LOCAL EXPANSION OF THE MTB POPULATION. THE NEUTRAL ENVIRONMENT OF THE LESION CORE VERSUS THE SLIGHTLY ACIDIC MACROPHAGE PHAGOSOME COMPARTMENT MAY REPRESENT A MECHANISM FUELING THIS MTB GROWTH. ELUCIDATING HOW MACROPHAGE SUBTYPES ACT TO RESTRICT MTB GROWTH WITHIN LESIONS, AND HOW MTB STRESS RESPONSES AND ADAPTATION RELATES TO MACROPHAGE SUBTYPES IN SITU, AT THE SINGLE BACTERIUM LEVEL, IS THUS CRITICAL FOR UNDERSTANDING MTB INFECTION BIOLOGY. USING THE C3HEB/FEJ MURINE INFECTION MODEL THAT RECAPITULATES CANONICAL HUMAN MTB LESIONS, I WILL ELUCIDATE HOW AM/IM DISTRIBUTION IN THESE LESIONS OVER TIME RELATE TO CHANGES IN MTB EXPOSURE TO NO/HYPOXIA, ACIDIC PH STRESS, AND LIPID UTILIZATION, WHICH ALL HAVE BEEN SHOWN TO AFFECT MTB GROWTH IN VITRO. TO FURTHER PROBE THE ROLE OF MACROPHAGES IN CONTAINING MTB GROWTH WITHIN NECROTIC LESIONS, MACROPHAGE DEPLETION WILL BE PERFORMED AFTER LESIONS HAVE FORMED, WITH TESTS OF INDUCIBLE KNOCKDOWN MTB MUTANTS IN KEY LIPID/PH REGULATORS TO PROVIDE MECHANISTIC INSIGHT INTO HOW DISRUPTION OF THESE PATHWAYS CAN ALTER THE ABILITY OF MTB TO ADAPT FOR SURVIVAL AND GROWTH IN NECROTIC LESIONS. THIS PROPOSAL USES QUANTITATIVE IN SITU MRNA TRANSCRIPT VISUALIZATION TECHNIQUES TO ASSESS HOW IMMUNE CELLS SPATIOTEMPORALLY DRIVE KEY ASPECTS OF THE LOCAL ENVIRONMENT THAT IMPACT MTB GROWTH IN NECROTIC LESIONS, KNOWLEDGE VITAL TO THE DEVELOPMENT OF MORE EFFECTIVE ANTI-TUBERCULAR THERAPEUTIC REGIMENS. COMPLETION OF THE PROPOSED STUDIES WILL PROVIDE THE NECESSARY TRAINING IN HOST-PATHOGEN INTERACTIONS TO ENABLE ME TO TRANSITION TO STARTING MY OWN INDEPENDENT LABORATORY AT A RESEARCH-INTENSIVE INSTITUTION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.4k | 8/22/25 | ||
| Not listed | $74.6k | 7/29/25 |